BMJ Open by VILLA, Antoine et al.
1Villa A, et al. BMJ Open 2019;9:e033040. doi:10.1136/bmjopen-2019-033040
Open access 
Study protocol for the assessment of 
nurses internal contamination by 
antineoplastic drugs in hospital centres: 
a cross- sectional multicentre 
descriptive study
Antoine Villa,1,2,3 Mathieu Molimard,1,3,4 Emmanuelle Bignon,5 Béatrice Martinez,1,3 
Magali Rouyer,5 Simone Mathoulin- Pelissier,1,3 Isabelle Baldi,1,3,6 
Catherine Verdun- Esquer,6 Mireille Canal- Raffin  1,3,4
To cite: Villa A, Molimard M, 
Bignon E, et al.  Study protocol 
for the assessment of nurses 
internal contamination by 
antineoplastic drugs in 
hospital centres: a cross- 
sectional multicentre 
descriptive study. BMJ Open 
2019;9:e033040. doi:10.1136/
bmjopen-2019-033040
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2019- 
033040).
Received 17 July 2019
Revised 18 September 2019
Accepted 07 October 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Mireille Canal- Raffin;  
 mireille. canal- raffin@ u- 
bordeaux. fr
Protocol
© Author(s) (or their 
employer(s)) 2019. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
Strengths and limitations of this study
 ► For reliable detection and to reduce the number of 
misclassifications as uncontaminated, the analytical 
methods used will to be specific, highly sensitive, 
will use isotopic internal standard to normalise urine 
matrix effect and the antineoplastic drugs (AD) urine 
stability during storage will be studied.
 ► Exposure biomarkers of five ADs will be analysed in 
each urine sample and AD concentration will be ex-
pressed in ng/L and in ng/g of urinary creatinine to 
account for urine dilution.
 ► The care departments of the study are selected 
among different medical specialties.
 ► The data from the self- questionnaires coupled with 
the results of the urine assays will serve to identify 
factors associated with internal contamination.
 ► This study will only assess the internal contamina-
tion of nurses and the environmental contamination 
of working surface will be performed separately in 
an other study.
AbStrACt
Introduction Antineoplastic drugs (AD) are potentially 
carcinogenic and/or reprotoxic molecules. Healthcare 
professionals are increasingly exposed to these drugs 
and can be potentially contaminated by them. Internal 
contamination of professionals is a key concern 
for occupational physicians in the assessment and 
management of occupational risks in healthcare 
settings. Objectives of this study are to report AD internal 
contamination rate in nursing staff and to identify factors 
associated with internal contamination.
Methods and analysis This trial will be conducted in two 
French hospital centres: University Hospital of Bordeaux 
and IUCT- Oncopole of Toulouse. The target population 
is nurses practicing in one of the fifteen selected care 
departments where at least one of the five studied AD is 
handled (5- fluorouracil, cyclophosphamide, doxorubicin, 
ifosfamide, methotrexate). The trial will be conducted with 
the following steps: (1) development of analytical methods 
to quantify AD urine biomarkers, (2) study of the workplace 
and organization around AD in each care department 
(transport and handling, professional practices, personal 
and collective protection equipments available) (3) 
development of a self- questionnaire detailing professional 
activities during the day of inclusion, (4) nurses inclusion 
(urine samples and self- questionnaire collection), (5) urine 
assays, (6) data analysis.
Ethics and dissemination The study protocol has 
been approved by the French Advisory Committee on the 
Treatment of Information in Health Research (CCTIRS) 
and by the French Data Protection Authority (CNIL). 
Following the opinion of the Regional Committee for the 
Protection of Persons, this study is outside the scope of 
the provisions governing biomedical research and routine 
care (n°2014/87). The results will be submitted to peer- 
reviewed journals and reported at suitable national and 
international meetings.
trial registration number NCT03137641.
IntroduCtIon
The number of cancer cases is constantly 
increasing worldwide and consequently, the 
administration of antineoplastic drugs (ADs) 
is more and more widespread. In France, 
more than 320 000 people were treated with 
AD in 2015.1 This leads to an increase in the 
use of these products by health professionals 
in terms of frequency and quantities handled 
and therefore to an increase in occupational 
exposure to these substances. According to 
the Sumer survey conducted with occupa-
tional physicians in 2010, more than 49 400 
employees were potentially exposed to these 
drugs in France2 and more than 5.5 million 
employees in the USA in 2003.3 Several 
professions are concerned by this exposure, 
including pharmacist technicians, phar-
macists, couriers, nurses, assistant nurses, 
hospital agents and doctors.
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More than 100 ADs are currently marketed.4 Most are 
on the list of ‘dangerous to handle’ medicines issued by 
the US National Institute for Occupational Research and 
Safety in 20043 because of their carcinogenic, mutagenic 
and/or reprotoxic effects (CMR). Thirty- eight ADs have 
been evaluated by IARC: 13 are classified as a human 
carcinogens (group 1), 11 as probably carcinogen (group 
2A), 7 may be carcinogenic (group 2B) and 7 are not clas-
sifiable for human carcinogenicity (group 3).
Since the 1970s, epidemiological studies conducted 
with nurses handling AD have shown an increase in 
risk of cancers5 6 such as leukemias5 and/or reprotoxic 
effects. The reported reprotoxic effects are: sponta-
neous abortions,7–13 fetal malformations,6 14–17 decreased 
fertility,13 18 19 risk of uterine growth retardation and 
prematurity.19
Several international studies conducted between 
the 1980s and 2003 report that pharmacist assistants 
and nurses handling these drugs were contaminated, 
with rates exceeding 75% or even 90% of staff in some 
studies.20–22 Moreover, numerous studies show surface 
contamination of workplace.23
Surface sampling is a useful tool in order to identify 
sources of environmental contamination, to help in the 
implementation of corrective measures, to verify the 
effectiveness of the surface decontamination process and 
to insure a monitoring of these surfaces. Surface sampling 
is complementary to biomonitoring, which is the best 
approach to measure internal contamination, that is, AD 
detection in urines of exposed healthcare professionals. 
Indeed, unlike metrology of surface contamination, 
biomonitoring allows to take into account at the level 
of each individual, all exposure pathways (respiratory, 
dermal and oral), the wearing or not of the protective 
equipment, the effectiveness of the type of protective 
equipment, gestures and professional practices, personal 
hygiene and quantities handled. Several analytical 
methods have been published for surface metrology of 
AD24–28 and for AD urine biomonitoring.29–32 More than 
17 ADs or their urine metabolites can be detected with 
these methods. The limit of detection (LOD) value in 
urine, for six of them, is from 0.0132–34 to 0.02 ng/L.35 
For the others, the LOD value in urine is from 0.05 to 
1 ng/L.36
In the absence of reference biological value for occupa-
tional AD exposure, the long- term effects of occupational 
low- intensity exposure to these CMR products should lead 
to a reduction in exposures to the lowest possible level.
During occupational exposure, the contamination can 
take place by the respiratory and/or cutaneous and/
or oral route.23 It can occur directly during the recep-
tion, preparation, transport, injection of the drug and 
the handling of waste or indirectly through the patients 
and their excreta (vomit, urine, stool, sweat), sheets and 
soiled linen.23 37 In order to limit these exposures and 
to guarantee the safety of employees, centralised recon-
stitution units for chemotherapies have been created in 
healthcare establishments and recommendations have 
been drawn up by government agencies and other occu-
pational health organisations.3 38 Despite the recommen-
dations and the improvements made in terms of safety on 
the handling and transport of these drugs, several recent 
studies show that the problem of contamination is still 
relevant, both in the working environment23 39–43 and for 
the professionals themselves.33 35 39 44–51 Currently, scien-
tific reviews report that there is no significant correlation 
between AD surface monitoring and AD urine moni-
toring.40 In this context, there is no disadvantage in 
conducting both studies separately.
Above reported internal contamination, data show 
that preventive measures are not currently sufficiently 
controlled, confirmed by Graeve et al.52 It is, thus, neces-
sary to understand the determinants of exposure.
Very little current data are available on the internal 
contamination of French healthcare professionals 
exposed to AD. The protocol detailed in this paper, aims 
to collect data on AD internal contamination in nurses and 
understand factors associated with this contamination.
objECtIvES
The main objective of this protocol is to evaluate the rate 
of internal contamination by AD in nurses administering 
AD and/or taking care of patients treated with these mole-
cules, in two French hospitals. This rate will be described 
globally and then stratified by care department.
The secondary objectives are: (1) to describe for each 
studied AD the rate of internal contamination among the 
nurses in the study, and the concentrations associated 
with this contamination; (2) to identify factors associated 
with internal contamination in this study (exposure char-
acteristics and use of protective equipments by nurses).
MEthodS And AnAlySIS
This study is a cross- sectional, descriptive, prospective 
multicentre study conducted in two French hospitals 
(University Hospital of Bordeaux and University Cancer 
Institute of Toulouse (IUCT)- Oncopole).
Eleven hospitals care departments, having an activity 
in the management of patients with cancer treated with 
any of the following AD: cyclophosphamide, ifosfamide, 
methotrexate, 5- fluorouracil and/or doxorubicin, were 
chosen for this study.
The target population is nurses occupationally exposed 
to the studied AD.
ElIgIbIlIty CrItErIA
The three following inclusion criteria are required: (1) be 
a nurse practising in one of the selected care departments 
where at least one of the five studied AD is handled; (2) 
handle at least one of the five studied AD and/or take 
care of a patient treated with one of the five studied AD 
on the day of study participation (ie, day of urine samples 
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Table 1 Collected data from the self- questionnaire 
administered to nurses concerning AD handling the day of 
inclusion (the day of urine sample collection)
Day of AD handling
Work schedule the previous 7 
days
 ► Day of sample urine 
collection
 ► Work*/no work (detailed 
for each 7 days)
Work shift  ► Hour of the beginning
 ► Hour of the end
Exposure/manipulation to any 
of the five AD*
Name of AD handling
Performed tasks (for each task 
the n° of task and AD nature 
are specified):
 ► AD infusion bags 
reception
 ► Opening of the package 
of AD infusion bags
 ► AD infusion
 ► Use of closed system 
transfer device
 ► Tubing purge
 ► Adjustment of the tubing 
flow
 ► Tubing disconnection
 ► Unscrewing needle
 ► Deposit of AD waste in 
bin
 ► Bin evacuation
Total handled amount (in mg) Detailed data for each AD







Perception of each participant on the department activity
Accidental exposure event*† 
(ex: needlestick, reversal or 
leakage of pockets…),
 ► Event nature and n° of 
events
 ► AD concerned by this 
event
 ► Associated clinical 
symptoms
 ► Declared event to 
occupational physician
*Data will also be collected for the 7 days prior to the day of study 
participation.
†Data will also be collected for all the career.
AD, antineoplastic drugs; IM, Intramuscular; IV, Intravenous.
Table 2 Collected data from the self- questionnaire 
administered to nurses concerning take care modalities of 
AD- treated patients the day of inclusion (the day of urine 
sample collection)
N° of treated 
patients who 
received an studied 
AD (n° and AD 
nature) that nurse 
has taking care the 
day of participation
 ► Patient treatment on the day of 
participation.
 ► Patient treatment within the 7 days 
before the day of participation.
Performed tasks:  ► Direct contact with treated patients 
(help to wash, handling of treated 
patient)
 ► Handling of treated patient excreta 
(vomit, urine, faeces, expectoration, 
soiled sheets)
 ► Participation in cleaning 
chemotherapy treatment room
 ► Cleaning room of treated patient
 ► Cleaning sanitary facilities of treated 
patient
 ► Insertion or removal of an urinary 
catheter
 ► Change of drape or bed repair of a 
treated patient
 ► Deposit of treated patient excreta 
in bin
 ► Bin evacuation.
AD, antineoplastic drugs.
collection) and (3) agree to participate in the study and 
sign the participation consent form.
Some work tasks (table 1) expose workers more than 
others (table 2) in term of level of AD concentration 
(AD preparation, patient’s urine, washing water after 
the patient had been washed and cleaning water after 
a patient toilet had been cleaned, …).37 However, the 
industrial sanitary rules (smoking, washing hands and 
onychophagia…) and the wearing of personal protective 
equipment (PPE) according to the tasks are not always 
respected. As a result, some less exposing tasks may cause 
higher workers contamination level than more exposing 
tasks. Indeed, Fransman et al,37 highlight levels of external 
hand contamination higher for tasks such as washing 
treated patients, removing bed sheets and handling 
urine of treated patients compared with drug prepara-
tion and toilet cleaning tasks. Therefore, for the second 
inclusion criteria, all nurses will be included whatever the 
task done (AD handling and/or take care of AD- treated 
patient) during the day of the participation to the study 
participation.
The exclusion criteria are: (1) be a student nurse; (2) 
be treated with one of the five studied AD or have been 
treated with any in the year prior to the day of study 
participation and (3) have at home a person treated with 
one of the five studied AD, in the month before the day 
of study participation.
Study dESIgn
The study will be conducted in six steps.
Step 1: development of analytical methods for quantification 
of Ad urine biomarkers
Analytical methods will be developed in the Pharma-
cology and Toxicology Laboratory of the Bordeaux 
University Hospital in accordance to the European 
Medecines Agency (EMEA) guideline.53 These methods 
use an ultra- high- performance liquid chromatography 
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Occupational data  ► Diplomas and specialisations: type 
and years of obtaining
 ► Seniority at the workplace: n° of 
years
 ► N° of years of AD handling and/or 
taking care patient treating by AD
 ► Current status
 ► Care department
 ► Establishment
 ► Received information on the risks 
related to AD and years of the 
information
 ► Received awareness on the risks 
related to AD handling and years of 
the awareness
 ► Level perception on AD exposing 
tasks, AD handling risks, the 
individual protective equipments, the 
action to be taken in AD accidental 
exposure cases
 ► Data on AD accidental exposures 
during their career.
AD, antineoplastic drugs.
system coupled with tandem mass spectrometry char-
acterised by high sensitivity and high specificity (5500 
QTrap, Sciex). AD urine biomarkers will be the AD them-
selves with the exception of 5- fluorouracil, which is not 
detectable in urine. For this molecule, its urinary metab-
olite, alfa- fluoro- beta- alanine (FBAL), will be assayed to 
assess internal contamination. Two methods have been 
already validated33 but the limit of quantification (LOQ) 
will be improved. Two other methods are developed for 
this study for the determination of 5- fluorouracil metab-
olite (FBAL)35 and doxorubicin urine biomarkers. These 
methods will be robust and highly sensitive with LOQ 
adapted to this type of study, that is, very low LOQ values 
allowing detection of urine AD traces of the order of 
ng/L.
For each AD, isotopic internal standard is added in each 
urine sample to normalise urine matrix effect. Stability of 
each AD in urine sample is studied under different condi-
tions of storage (+20°C for 24 hours with and without light, 
at +4°C for 72 hours, at −20°C for 1 month and 1 year, and 
after three freeze- thaw cycles in urine). A postprepara-
tive stability was conducted by analysing extracted urine 
samples kept under auto- sampler conditions (+15°C) for 
72 hours.
Step 2: study of the workplace and organisation around Ad in 
each care department
A hygienist of the occupational medicine department 
will observe the activities around AD in each selected 
care department at the end of the urine sample and 
self- questionnaire collection. Collective and individual 
protection equipment available in each department 
as well as the professional practices observed will be 
reported in this study of the workplace. A description 
of the complete organisation around AD and excreta of 
treated patients within each care department will also be 
carried out: AD reception in the department, administra-
tion to patients, disposal of waste. All these observations 
will be collected and reported in a standardised way for 
each care department.
Step 3: development of a self-questionnaire
A self- questionnaire is built, in the light of literature data, 
concerning work tasks potentially exposing, risk percep-
tion.49 50 54–58 In addition, we conducted a pilot study in 
a healthcare unit that enabled us to carry out a study of 
the complete organisation around AD and excreta of 
treated patients and to collect tasks performed, type and 
wearing of PPE. During this pilot study, a draft version was 
pretested on a small group of nurses. When it was neces-
sary, questions were changed according to the feedback 
of the nurses. A final version was elaborated and will be 
used in this study.
The aim of this self- questionnaire is to collect several 
data: sociodemographic and occupational data (table 3), 
data concerning AD handling on the day of inclu-
sion (table 1), data concerning take care modalities of 
AD- treated patient (table 2) and PPE worn the day of 
inclusion (table 4).
For each task listed in tables 1 and 2, the influence of 
the questionnaire on the nurse practices on the day of 
participation and for the future is asked. For each task 
listed in tables 1 and 2, PPEs (table 4) that the nurse wears 
the day of inclusion are asked. For each task the PPE list is 
exhaustive so as not to influence the nurse in the choice 
of PPE according to the task.
Step 4: nurses inclusion
Each nurse from the selected healthcare departments 
will receive a briefing note prior to inclusion and will be 
invited to participate in an information meeting about 
this study. At the end of the meeting, a kit containing 
the polypropylene pots to collect urine samples, the self- 
questionnaire and the participation consent form will be 
given to each volunteer. During the meeting, the nurse 
will be asked to collect their urine samples after several 
days of work. Therefore, the self- questionnaire plans to 
collect data on work history the previous 7 days before 
urine samples collection (type of studied AD handling, 
accidental exposure event). For each nurse, the study 
participation lasts 24 hours.
Three urine samples will be collected at different times 
in less than 24 hours (figure 1): the first one within the 
3 hours before the start of the work to document an 
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Figure 1 Urine samples collection time. D, day of participation of nurses in the study; swt, start work time; ewt, end work time; 
S1, urine sample collected within 3 hours before the start of the work; S2, urine sample collected within 2 hours following the 
end of the work; S3, urine sample collected between 7 and 10 hours following the end of the work.
Table 4 Collected data from the self- questionnaire 
administered in nurses concerning personal protective 
equipment* (PPE) wearing the day of inclusion†
Wearing and type of clothing  ► Hat
 ► Plasticised apron
 ► Short sleeve gown
 ► Long sleeve gown
Wearing and type of mask  ► Surgical mask
 ► FFP2 mask
 ► FFP3 mask
Wearing and type of eye 
protection
 ► Protective eyewear
 ► Visor
Wearing and type of gloves  ► - Latex/vinyl/nitrile/ 
polyvinyl chloride
 ► Simple pair or double 
pairs of gloves
 ► Short or long sleeve
Performed procedure of hand 
washing after gloves removal 
(gloves used after AD handling)
 ► Nothing
 ► Hand sanitizer use
 ► Wash of hands with 
water only
 ► Wash of hands with 
water and soap
*PPE list proposed to each nurse for each performed task.
†For each item the use frequency is ask (never, sometimes, 
systematically).
‡
AD, antineoplastic drugs; FFP, Filtering Facepiece Particles.
internal contamination following exposure the previous 
days before the study; the second within 2 hours following 
the end of the work, to document an internal contami-
nation following exposure during the first hours of the 
day working day; the third between 7 and 10 hours after 
the end of the work, to document an internal contamina-
tion following exposure at the end of the work. The time 
of the third sampling was chosen to take into account a 
delayed absorption by the cutaneous way as indicated by 
Hirst et al.59
A document gathering the date and times of urine 
samples will be attached to the samples. Urine samples 
will be sent to the pharmacology and toxicology labo-
ratory of Bordeaux university hospital within 72 hours 
at +4°C. Then samples will be aliquoted and stored 
at −20°C until analysis. At the same time, nurses 
will complete a self- questionnaire concerning their 
professional activity throughout the AD handling day. 
The self- questionnaire is a paper document with a 
detachable flap. This part will be sent by mail (return 
postage paid envelopes) to the coordinating centre, 
which will monitor the completed data and the other 
part will be kept by the nurse. After urine sample 
reception by the laboratory, the latter will immedi-
ately informs the coordinating centre of this recep-
tion. The coordinating centre will contact the nurses 
within 7 days if the self- questionnaire has not been 
received yet, limiting possible loss of data. Moreover, 
in case of missing or discordant data, each subject will 
be contacted by a member of the coordinating centre 
to complete the self- questionnaire.
Step 5: urine assays
For each urine sample, four extraction methods followed 
by a validated analytical method will be performed. 
Moreover, urine creatinine will be analysed for each 
urine sample to account for dilution.60 61 The result will 
be expressed according to the AD concentration level 
(ng/L and ng/g of urinary creatinine). Participant will 
be considered as contaminated when at least one of the 
five studied AD, is detected in at least one of the three 
collected urine samples.
Step 6: data analysis
Statistical analysis will be performed using SAS software 
(SAS Institute, V.9.3) by a statistician from the coordi-
nating centre.
The rate of internal contamination will be calculated 
by reporting the number of contaminated subjects by 
at least one of the studied AD to the total number of 
subjects included and will be expressed as a percentage. 
This proportion will be estimated globally then detailed 
by molecule and department. The extent of the concen-
tration levels achieved will also be described for each 
sampling time and each drug.
The statistical analysis will include a global 
descriptive analysis of collected data from the self- 
administered questionnaire. Then factors associated 
with internal contamination of nurses will be studied 
using a multivariate logistic regression model. An 
univariate analysis will be used to select the variables, 
which will be included into the multivariate model at 
the significance level of 25%. A step- by- step method 
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will be used to select the significant variables at the 
5% threshold in the final multivariate model. Inter-
actions and confounders will be sought and tested 
throughout the modelling.
EndpoIntS
The primary endpoint will be the absence or presence of 
internal AD contamination for each nurse. It will be deter-
mined in the light of AD urine assays results. A subject will 
be considered contaminated if at least one of the five AD 
is detected in at least one of the three urine samples.
Others endpoints will be studied:
 ► AD internal contamination stratified by drug and by 
sampling times (S1, S2 and S3).
 ► Descriptions of the studied population from the self- 
questionnaire data: (1) sociodemographic data; (2) 
occupational data; (3) AD handling data and (4) take 
care modalities of treated patients by studied AD. This 
description will be stratified by centre and by depart-
ment (stratification conditioned by the number of 
participants).
Following these descriptions, the factors, described 
above, associated with internal contamination of nurses 
will be studied.
Calculation of the number of participants
The main objective is to estimate the rate of nurse internal 
AD contamination in two hospitals. Thus, no sample size 
calculation will be made for the main criterion since it 
will be estimated from the total eligible population. Given 
the total number of nurses working in the 11 selected 
care departments to participate in the study, 300 nurses 
are potentially eligible.
Since this protocol is not very constraining for partici-
pants, with only 1 day of inclusion and only three nonin-
vasive urinary samples, we expect a participation rate 
around 75% for the nursing staff. With this participation 
rate, the number of recruited subjects expected for this 
study will be about 225 subjects.
Impact of the study
The impact of this study will be: (1) the assessment of 
the rate of nurses internal contamination in care depart-
ments, (2) awareness of nurses about their contami-
nation, (3) implementation of corrective actions, (4) 
improvement of AD handling and transport safety, (5) 
improvement of nurse professional practices and partic-
ularly the use of protection equipment, (6) powerful 
(highly sensitive) analytical tools set up in the labora-
tory, adapted to the follow- up of professionals exposed 
to ‘dangerous handling drugs’ and available for occupa-
tional physicians.
patient and public involvement
The research question and the protocol have been devel-
oped by a multidisciplinary team and an analysis of the 
workplace. As indicated in step 3 of the study protocol, 
a pilot study was previously conducted, in a health-
care unit of Bordeaux university hospital during which 
a draft version of a self- questionnaire was developed 
and pretested on a small group of nurses and modify 
according to their feedback.
Representative workers of hospital personnel, managers 
of the two hospitals, health managers will be informed of 
the study. Each nurse from the selected care departments 
will receive a briefing note prior to inclusion and will be 
invited to participate in an information meeting about 
this study.
Ethics and dissemination
Collected data will be subject to a computerised 
treatment in the Coordinating Centre of this study 
(Research Platform in Pharmacoepidemiology, BPE, 
CIC Bordeaux CIC1401) in compliance with law n° 
78–17 (6 January 1978) relating to data processing, 
files and freedoms modified by the French law 2004–
801 (6 August 2004). Collected data will be kept 
during 5 years.
The results from this study will be submitted to peer- 
reviewed journals and reported at suitable national and 
international conferences or workshops.
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